Abstract
This study examines mainstream news coverage of the direct-to-consumer advertising phenomenon since FDA deregulation of such ads in 1997, and helps illuminate framing of stakeholder claims. The authors found that prominent frames describe drawbacks and benefits of DTC ads in addition to power relationships between the Food and Drug Administration and drug companies. Sources most likely to be quoted were representatives of the pharmaceutical industry. The authors argue that issues such as consumer interests and ethics are overshadowed by special interests, and that balanced coverage is narrow in scope. The authors use both qualitative and quantitative methods to examine frames in-depth and to explore relationships among frames.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
